US009409934B2

(12) **United States Patent**
Seth et al.

(10) **Patent No.: US 9,409,934 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **CYCLOHEXENYL NUCLEIC ACIDS ANALOGS**

(71) Applicant: **Ionis Pharmaceuticals, Inc.**, Carlsbad, CA (US)

(72) Inventors: **Punit P. Seth**, Carlsbad, CA (US); **Eric E. Swayze**, Encinitas, CA (US)

(73) Assignee: **Ionis Pharmaceuticals, Inc.**, Carlsbad, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 145 days.

(21) Appl. No.: **14/069,773**

(22) Filed: **Nov. 1, 2013**

(65) **Prior Publication Data**

US 2014/0073786 A1 Mar. 13, 2014

Related U.S. Application Data

(62) Division of application No. 13/063,917, filed as application No. PCT/US2009/058011 on Sep. 23, 2009, now Pat. No. 8,604,192.

(60) Provisional application No. 61/150,504, filed on Feb. 6, 2009, provisional application No. 61/099,846, filed on Sep. 24, 2008.

(51) **Int. Cl.**

C07D 473/34	(2006.01)
C07D 473/18	(2006.01)
C07D 239/54	(2006.01)
C07D 239/47	(2006.01)
C07F 9/24	(2006.01)
C07H 19/04	(2006.01)
C07H 21/00	(2006.01)
C07F 9/22	(2006.01)
C07F 9/6512	(2006.01)
C07F 9/6561	(2006.01)

(52) **U.S. Cl.**

CPC ***C07F 9/24*** (2013.01); ***C07D 239/47*** (2013.01); ***C07D 239/54*** (2013.01); ***C07D 473/18*** (2013.01); ***C07D 473/34*** (2013.01); ***C07F 9/22*** (2013.01); ***C07F 9/65127*** (2013.01); ***C07F 9/65616*** (2013.01); ***C07H 19/04*** (2013.01); ***C07H 21/00*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,687,808	A	8/1972	Merigan et al.
4,415,732	A	11/1983	Caruthers et al.
4,458,066	A	7/1984	Caruthers et al.
4,469,863	A	9/1984	Ts'o et al.
4,476,301	A	10/1984	Imbach et al.
4,500,707	A	2/1985	Caruthers et al.
4,668,777	A	5/1987	Caruthers et al.
4,725,677	A	2/1988	Koster et al.
4,845,205	A	7/1989	Huynh et al.
4,973,679	A	11/1990	Caruthers et al.
4,981,957	A	1/1991	Lableu et al.
5,013,830	A	5/1991	Ohutsuka et al.
5,023,243	A	6/1991	Tullis
5,034,506	A	7/1991	Summerton et al.
5,118,800	A	6/1992	Smith et al.
5,130,302	A	7/1992	Spielvogel et al.
5,132,418	A	7/1992	Caruthers et al.
5,134,066	A	7/1992	Rogers et al.
RE34,069	E	9/1992	Koster et al.
5,149,797	A	9/1992	Pederspn et al.
5,166,315	A	11/1992	Summerton et al.
5,175,273	A	12/1992	Bischofberger et al.
5,177,196	A	1/1993	Meyer, Jr. et al.
5,177,198	A	1/1993	Spielvogel et al.
5,185,444	A	2/1993	Summerton et al.
5,188,897	A	2/1993	Suhadolnik et al.
5,194,599	A	3/1993	Froehler
5,214,134	A	5/1993	Weis et al.
5,216,141	A	6/1993	Benner
5,220,007	A	6/1993	Pederson et al.
5,223,618	A	6/1993	Cook et al.
5,235,033	A	8/1993	Summerton et al.
5,256,775	A	10/1993	Froehler
5,264,423	A	11/1993	Cohen et al.
5,264,562	A	11/1993	Matteucci
5,264,564	A	11/1993	Matteucci
5,276,019	A	1/1994	Cohen et al.
5,278,302	A	1/1994	Caruthers et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO 94/02499	2/1994
WO	WO 94/17093	8/1994

(Continued)

OTHER PUBLICATIONS

Altschul et al., "Basic Local Alignment Search Tool" J. Mol. Biol. (1990) 215:403-410.

Barany et al., "A New Amino Protecting Group Removable by Reduction. Chemistry of the Dithiasuccinoyl (Dts) Function" J. Am. Chem. Soc. (1977) 99:7363-7365.

Barany et al., "Kinetics and Mechanisms of the Thiolytic Removal of the Dithiasuccinoyl (Dts) Amino Protecting Group" J. Am. Chem. Soc. (1980) 102:3084-3095.

Bass, "Double-stranded RNA as a template for gene silencing" Cell (2000) 101:235-238.

Beaucage et al., "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach" Tetrahedron (1992) 48:2223-2311.

(Continued)

Primary Examiner — Eric Olson

(74) *Attorney, Agent, or Firm* — McNeill Baur PLLC

(57) **ABSTRACT**

The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclohexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

20 Claims, No Drawings